#IJSOvisualabstract2025 #Gastriccancer Decoding recurrence pattern in Gastric cancer: Insights beyond resection Penned by #TeamBRAIRCH Detailed read here doi.org/10.1007/s13193… #medtwitter #cancersurgery

VATS Esophagectomy and Total mediastinal lymph node dissection - empasis on supracarinal and RLN dissection . Watch our technique at youtu.be/gPtkSibbaeo?fe… Shailesh V. Shrikhande Devayani Niyogi Swapnil Patel Vishwas Pai Shravan Sharad Nadkarni Vivek Sukumar Nawaz

VATS+LAP Ivor Lewis for Lower Esophageal cancer Watch our technique at youtu.be/wRlkaBd7Drc?fe… Shailesh V. Shrikhande Devayani Niyogi Swapnil Patel Vishwas Pai Pavan Sugoor Shravan Sharad Nadkarni Rajesh S Shinde Vivek Sukumar sanket bankar Nawaz

COPS 2025 - Conference on peritoneal surface oncology - the stage is set for 2 days of academic extravaganza in the beautiful town of Namakkal, 🇮🇳! Stars 🌟 have reached…. all PSM enthusiasts of the nation geared for 2 days of rich academia! glen Vahan Képénékian

Great opportunity of discussing a difficult clinical scenario - advanced rectal cancer with poor diff with peritoneal ds ! Join Peritoneal Surface Oncology Group International case discussion here online with Paul H Sugarbaker !

Here we go.. #PSOGICASE Paul H Sugarbaker Swapnil Patel ➡️23 year gentleman ➡️No comorbidities, no previous surgery ➡️No contributory family history ➡️Presents with bleeding P/R - 3 months and spurious diarrhea – 1 month Clinical examination: ➡️ECOG 1 ➡️DRE – growth starting at 3

Swapnil Patel Paul H Sugarbaker Peritoneal Surface Oncology Group International @LahayeMax #CRCTrialsChat Alvaro Arjona Dr.Mohammad ALYAMI Mohammad AlShahrani Andreas Brandl Lana Bijelic Cesar Nevarez Graber Delia Cortés Guiral It could be a risk for peritoneal involvement if the lesion goes Intraperitoneal.

Peritoneal Surface Oncology Group International Swapnil Patel @LahayeMax #CRCTrialsChat Alvaro Arjona Dr.Mohammad ALYAMI Mohammad AlShahrani Andreas Brandl Lana Bijelic Cesar Nevarez Graber Delia Cortés Guiral Asociación Peritoneum European Society of Coloproctology Faheez Mohamed Faraz Khan Mufaddal Kazi Andrei Nikiforchin, MD Ankit Dhiman Luis Felipe Falla Dr Nabila Ansari Starting with FOLFORINOX and assessing its effect on the primary disease is the starting point. Radiation therapy is unlikely to give local control with this very large tumor. With a systemic chemotherapy response I would move to resection of all the disease.

Peritoneal Surface Oncology Group International Swapnil Patel @LahayeMax #CRCTrialsChat Alvaro Arjona Dr.Mohammad ALYAMI Mohammad AlShahrani Andreas Brandl Lana Bijelic Cesar Nevarez Graber Delia Cortés Guiral Asociación Peritoneum European Society of Coloproctology Faheez Mohamed Faraz Khan Mufaddal Kazi Andrei Nikiforchin, MD Ankit Dhiman Luis Felipe Falla Dr Nabila Ansari Steven D Wexner MD, PhD Pashtoon Kasi MD, MS Aparna Raj Parikh SoMe4Surgery The MIS approach and the open surgery approach are both excellent treatment options for this patient. The decision is made by the surgeon depending on his expertise. I would not think that one approach is markedly superior to the other.

Peritoneal Surface Oncology Group International Paul H Sugarbaker Swapnil Patel @LahayeMax #CRCTrialsChat Alvaro Arjona Dr.Mohammad ALYAMI Mohammad AlShahrani Andreas Brandl Lana Bijelic Cesar Nevarez Graber Delia Cortés Guiral Asociación Peritoneum European Society of Coloproctology Faheez Mohamed Mufaddal Kazi Andrei Nikiforchin, MD Ankit Dhiman Luis Felipe Falla Dr Nabila Ansari Steven D Wexner MD, PhD Pashtoon Kasi MD, MS Aparna Raj Parikh SoMe4Surgery That's a great outcome, all things considering.

Peritoneal Surface Oncology Group International Swapnil Patel @LahayeMax #CRCTrialsChat Alvaro Arjona Dr.Mohammad ALYAMI Mohammad AlShahrani Andreas Brandl Lana Bijelic Cesar Nevarez Graber Delia Cortés Guiral Asociación Peritoneum European Society of Coloproctology Faheez Mohamed Faraz Khan Mufaddal Kazi Andrei Nikiforchin, MD Ankit Dhiman Luis Felipe Falla Dr Nabila Ansari Steven D Wexner MD, PhD Pashtoon Kasi MD, MS Aparna Raj Parikh SoMe4Surgery This patient had a challenging primary cancer that was controlled. The PM were not controlled and will lead to his demise. Also, no liver metastases or systemic disease. We must identify alternatives to HIPEC that can maintain control within the peritoneal space. A high priority.

Always be vigilant and prepared.. imaging may not always pick up few details. Manish S Bhandare Gurudutt P. Varty ACTREC-TMC

Great case discussion on the Peritoneal Surface Oncology Group International virtual platform with Paul H Sugarbaker. Wonderfully moderated by Aditi Bhatt ! We identified many problem statements during the discusion and hopefully many pertinent studies on related topics coming out soon.

Delighted to continue the good run with this publication on Gen aspect & Technical considerations in CRS. Strong work !! Aditi Bhatt Swapnil Patel Dr SVS Deo arvind Prasanth Penumadu Vivek Sukumar Somashekhar SP IASO Academics Read 👇 doi.org/10.1007/s13193…

Join Indian and international experts in the fight against peritoneal cancer ! Renowned expert Prof. glen invites you to the 2025 INDEPSO ISPSM Annual Update in Kozhikode this June. Register Now !! …onealupdate2025.mvrcancerhospital.com

Looking forward to an excellent academic feast on PSM this summer ! Let evidence be the front runner in backing practice ! Aditi Bhatt Aarthi S Jayraj IGCS Peritoneal Surface Oncology Group International Peter Cashin sanket shah Shravan Sharad Nadkarni Mufaddal Kazi

🚨 New INDEPSO–ISPSM Consensus on Ovarian Cancer just published! 📝 link.springer.com/article/10.100… CRS & HIPEC are redefining survival outcomes in advanced/recurrent ovarian cancer. Join the conversation at #MVRCancon2025 — with dedicated sessions on Ovarian Cancer this year. 📅

"If you are interested in clinical research and looking for opportunities to collaborate, then this is a meeting that you should not miss" Dr Aditi Bhatt Aditi Bhatt INDEPSO Secretary, & Peritoneal Surface Oncology Group International member invites you to the *9th Annual Peritoneal Update* in Calicut ! 📅

Abstract submission deadline 19th May 2025. Email you 300 word structured abstracts to [email protected] Ind J Med Ped Oncology Young Oncologists Group India🇮🇳 SoMe4Peritoneum IASO Academics IJGC Fellows SoMe4GynOnc GYN Cancer | #GYNCSM Peritoneal Surface Oncology Group International News (PMP) Pseudomyxoma Peritonei Appendix Cancer RarasNoInvisibles Swapnil Patel

Indian Network for DEvelopment of Peritoneal Surface Oncology (INDEPSO) - Honoring the Star Acts of MVR CANCON 2025 glen Kurt Van der Speeten Peritoneal Surface Oncology Group International MVR Cancer Centre and Research Institute oncodaily.com/positive/mvr-c… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc